Vanguard Group’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-1,561,105
| Closed | -$33.9M | – | 4100 |
|
|
2017
Q2 | $33.9M | Buy |
1,561,105
+241,050
| +18% | +$4.37M | ﹤0.01% | 2214 |
|
|
2017
Q1 | $18.5M | Buy |
1,320,055
+79,155
| +6% | +$1.3M | ﹤0.01% | 2472 |
|
|
2016
Q4 | $23.3M | Buy |
1,240,900
+41,604
| +3% | +$707K | ﹤0.01% | 2359 |
|
|
2016
Q3 | $19.8M | Sell |
1,199,296
-71,834
| -6% | -$1.06M | ﹤0.01% | 2365 |
|
|
2016
Q2 | $17.1M | Sell |
1,271,130
-142,201
| -10% | -$2.07M | ﹤0.01% | 2398 |
|
|
2016
Q1 | $21.6M | Buy |
1,413,331
+271,624
| +24% | +$4.26M | ﹤0.01% | 2267 |
|
|
2015
Q4 | $22.7M | Buy |
1,141,707
+23,690
| +2% | +$450K | ﹤0.01% | 2255 |
|
|
2015
Q3 | $19.5M | Buy |
1,118,017
+72,120
| +7% | +$1.47M | ﹤0.01% | 2302 |
|
|
2015
Q2 | $21.1M | Buy |
1,045,897
+23,670
| +2% | +$457K | ﹤0.01% | 2331 |
|
|
2015
Q1 | $18M | Buy |
1,022,227
+142,170
| +16% | +$2.42M | ﹤0.01% | 2371 |
|
|
2014
Q4 | $14.3M | Sell |
880,057
-40,801
| -4% | -$749K | ﹤0.01% | 2394 |
|
|
2014
Q3 | $20.3M | Buy |
920,858
+48,275
| +6% | +$989K | ﹤0.01% | 2195 |
|
|
2014
Q2 | $17.6M | Buy |
872,583
+113,099
| +15% | +$1.92M | ﹤0.01% | 2263 |
|
|
2014
Q1 | $14.1M | Sell |
759,484
-431
| -0.1% | -$5.93K | ﹤0.01% | 2325 |
|
|
2013
Q4 | $7.66M | Sell |
759,915
-3,442
| -0.5% | -$41.6K | ﹤0.01% | 2573 |
|
|
2013
Q3 | $9.84M | Sell |
763,357
-33,420
| -4% | -$411K | ﹤0.01% | 2406 |
|
|
2013
Q2 | $9.46M | Buy |
+796,777
| New | +$8.63M | ﹤0.01% | 2354 |
|
Other funds holding AMRI
Vanguard Group's AMRI Position: Q3 2017 in Review
Vanguard Group sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 1,561,105 shares — an estimated $33.9M sold.
Vanguard Group first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $33.9M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- Vanguard Group reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- Vanguard Group sold 1,561,105 Albany Molecular Research Inc shares in Q3 2017, an estimated $33.9M.
- Vanguard Group first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
- Vanguard Group's Albany Molecular Research Inc position peaked at $33.9M in Q2 2017.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on Vanguard Group's 13F filing for Q3 2017, filed 14 Nov 2017.